Anika Therapeutics (ANIK) Other Operating Expenses (2010 - 2021)

Anika Therapeutics (ANIK) has reported Other Operating Expenses for 12 consecutive years, with $825000.0 the latest figure, recorded in Q4 2021.

• On a quarterly basis, Other Operating Expenses fell 93.06% year-over-year to $825000.0 in Q4 2021; TTM through Sep 2022 was $825000.0, a 108.22% increase from a year earlier, with the FY2021 full-year figure at -$21.1 million, down 252.27% from the prior year.
• Other Operating Expenses was $825000.0 for Q4 2021 at Anika Therapeutics, up from -$3.4 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $11.9 million in Q4 2020 and troughed at -$24.3 million in Q4 2018.
• A 5-year average of $1.0 million and a median of $6.0 million in 2017 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses surged 159.14% in 2020 and sank 425.31% in 2021, its largest moves.
• Over 5 years, Other Operating Expenses stood at $8.7 million in 2017, then sank by 378.56% to -$24.3 million in 2018, then advanced by 17.22% to -$20.1 million in 2019, then surged by 159.14% to $11.9 million in 2020, then slumped by 93.06% to $825000.0 in 2021.
• The last three Other Operating Expenses figures came in at $825000.0 (Q4 2021), -$3.4 million (Q3 2021), and -$13.6 million (Q2 2021), per Business Quant data.